Standard treatments have failed to crack glioblastoma multiforme (GBM). That is changing. A new research perspective in Oncoscience points to a sharp turn: the old model of broad cytotoxic therapy is fading. Precision medicine is moving in, targeting the tumor’s molecular and immune weak spots.
In September 2026, Beactica Therapeutics began IND-enabling studies for BEA-17, the first oral LSD1/CoREST degrader being developed as a precision immunotherapy for glioblastoma.
Researchers are zeroing in on targets like B7-H3, CDK4/6, the RAS/MAPK pathway, and BRAF mutations. Abemaciclib, a CDK4/6 inhibitor that can cross into the brain, is being tested with the ERK inhibitor LY3214996. Regorafenib, which edged out lomustine in the Phase 2 REGOMA trial for recurrent GBM, is under review for its survival impact, though it brings more side effects. The field is shifting to biomarker-driven choices. MGMT promoter methylation, IDH mutation, EGFR amplification, and BRAF V600E now help match patients to the right therapy for their tumor’s biology.
Bayer is still testing regorafenib in GBM through platform studies like GBM AGILE. In November 2025, Phase I REGOMA-2 data showed regorafenib combined with temozolomide and radiotherapy was tolerable for patients with MGMT-methylated, IDH wild-type GBM. This supports the move toward combination and biomarker-guided strategies. Details appear in a Barchart market summary.
Medicenna reported at SNO 2026 that Bizaxofusp (formerly MDNA55) has been studied in over 130 patients across five clinical trials, including a phase 2b study in recurrent glioblastoma.
Gene therapy and oncolytic viruses are also in play. Retroviral replicating vectors like DB107-RRV/DB107-FC are built to infect dividing tumor cells and activate prodrugs locally. Other gene therapies aim for both tumor targeting and immune activation. These are early-stage. Delivery and immune response management remain tough problems.
GBM’s ability to adapt its metabolism is under attack too. BPM31510 disrupts mitochondrial energy and redox balance. ASC40 blocks fatty acid synthase. Both are in clinical trials. These drugs try to cut off the tumor’s survival tactics in low-oxygen, low-nutrient conditions. That’s a key part of GBM’s toughness.
No new drug has replaced temozolomide as the mainstay of GBM care. Instead, the field is layering targeted, immune, or metabolic agents on top of standard treatment for patients with specific biomarkers. The authors sum it up: “The combination of precision molecular targeting with new immune activation methods and CNS-based drug delivery and metabolic interference establishes a foundation for developing combination therapies which should use proven predictive biomarkers for maximum effectiveness.”
Comparing trial results is messy. Eligibility, endpoints, imaging, and steroid use all differ. The authors say adaptive clinical trial platforms—able to test several therapies and molecular subgroups at once—may be needed for real progress. Liquid-biopsy and imaging biomarkers are starting to help track response and guide therapy changes in real time.
Other tough cancers show the same urgency. A reported earlier case of experimental CAR T-cell therapy for advanced colorectal cancer drives the point home. The lesson is simple. Only by breaking down the biological defenses of aggressive tumors with precision tools can the field move forward.
This review shows a GBM field in motion. Mechanism-based, biomarker-guided, and combination strategies are now shaping clinical trials. The obstacles are big: tumor diversity, immune suppression, metabolic flexibility, and the blood-brain barrier all block progress. Still, the push for molecular targeting, immune engineering, metabolic disruption, and smarter drug delivery is building a new base for GBM therapy. The next two years of Phase II and III trial results will show if these advances can finally break the deadlock that has held GBM treatment back for decades.
